Key Takeaways
- Verb Biotics employs a ‘function-first’ strategy to develop biotic solutions, focusing on health indications rather than specific strains.
- The startup has launched two innovative products, Keystone Postbiotic for gut health and GABA Probiotic LP815 for mood and stress regulation.
- There is growing consumer interest in genetically modified biotic solutions, indicating a shift in perceptions around efficacy and safety.
Innovative Approach to Probiotics
Verb Biotics, a microbiome health startup, adopts a unique strategy by prioritizing health outcomes over flagship strains, as stated by CEO Todd Beckman. Previously part of Ginkgo Bioworks, Beckman emphasizes a pharmaceutical-like model that starts by identifying health indications and the mechanisms of action necessary to support those conditions. This approach allows for the development of “precision biotics” designed for foods and supplements that produce measurable effects.
Founded in 2021, Verb Biotics received $30 million from Viking Global Investors and Cascade Investment to create products that integrate seamlessly into various consumer goods. The company screens countless microbial strains to isolate those capable of producing beneficial metabolites and is exploring synthetic biology techniques to optimize these processes.
Keystone Postbiotic for Digestive Health
The first product from Verb Biotics, Keystone Postbiotic, is a shelf-stable formulation composed of heat-inactivated probiotics. It includes strains that promote healthy gut bacteria and enhance gut barrier integrity, combating issues related to “leaky gut” that can lead to inflammation and digestive problems. Unlike traditional probiotics, Keystone is inert and can be incorporated into a wider range of non-refrigerated products, offering versatility across the market.
Produced through fermentation on oats and then heat-treated, Keystone is designed for easy use in gummies and functional beverages. With doses set at just 300 mg, it aims to alleviate gas and bloating, significantly lessening digestive discomfort compared to traditional prebiotic fibers. Early pilot data, including a human trial, suggest positive effects on gut health, with a larger trial expected to report outcomes soon.
GABA Probiotic LP815 for Mood and Stress
The second product, GABA Probiotic LP815, harnesses a Lactiplantibacillus strain capable of producing Gamma-Aminobutyric Acid (GABA), a key neurotransmitter that impacts mood and stress levels. Beckman elaborates on the strain’s effectiveness, highlighting its enhanced GABA production through a directed evolution program.
LP815 provides a sustained GABA release, making it distinct from many existing GABA supplements. Clinical trials focusing on stress and mood have yielded promising results, particularly regarding irritability. The product also shows potential benefits for pets, with early studies indicating reduced anxiety and aggression in dogs.
Future Developments and Consumer Sentiment
In addition to its Non-GMO offerings, Verb Biotics is exploring genetically modified biotics amid shifting consumer attitudes. Recent surveys suggest that efficacy and safety are becoming more critical to consumers than the presence of GM ingredients. Beckman notes a growing interest among major consumer packaged goods companies in GM options, indicating an evolving market landscape.
Verb Biotics continues to focus on developing technologies targeting various health areas, including gut and brain health, sleep, stress management, healthy aging, and women’s health, specifically around menopause. With robust funding and a strong product pipeline, the company is well-positioned to make significant strides in the biotic solutions market.
The content above is a summary. For more details, see the source article.
